Archives: BioMedWire

September 9, 2020 14:05:21

Research has shown that the alleviation of pain during an immunization procedure can improve the vaccine’s acceptance and also decrease the hesitancy of parents to vaccinate their children. Research on babies who are between 0 to 6 months shows that breastfeeding an infant during vaccine injections is an effective way of decreasing pain during routine immunizations.

Below, we look into how. . .

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

African Green Monkey Helps Battle Against COVID-19

September 9, 2020 13:06:51

A global pandemic has been experienced at the beginning of the year in which millions have been infected, and thousands have lost their lives. Coronavirus, as it is commonly known by many, has been a thorn in the flesh for all the countries since it does not have a vaccine or a specific cure. However, virologists have been trying their very best to develop a remedy for the SARS-COV-2, the causative agent of COVID-19.

Several animal models that may have the same symptoms of COVID-19 to those experienced in human beings have been used in several studies to carry out research that cannot be done in human beings. One of the animals that has been subjected to this task is the African green monkey. It has been noted that it possesses similar traits of human COVID-19. It will be very beneficial in helping the virologists and other researchers make a breakthrough in…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

180 Life Sciences Corp. is “One to Watch”

September 9, 2020 11:44:36

180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value
The company has a large and expanding patent portfolio
The risks associated with the company’s drug development efforts are mitigated through the concurrent advancement of multiple programs in different stages of development
180 Life Sciences decreases costs and expedites time to market through the use of grant funding, cost-effective international trials and recruitment of hospital-based luminaries who attract teams of excellence

KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (“SPAC”), announced that, in connection with its previously detailed merger agreement with 180 Life Sciences, it consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on August 28, 2020. It expects to close the business combination in Q4 2020. Following the merger, the company will be listed on the Nasdaq Capital Market under ticker symbol ‘ATNF’.

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the…

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Secures C$13.29M Through Previously Announced Offering

September 9, 2020 10:55:07

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today confirmed that it has closed its previously announced offering of units for aggregate gross proceeds of approximately C$13.29 million. According to the update, the company issued 15,640,000 units, each at a price of C$0.85, with each unit consisting of one common share of the company and ½ of one common share purchase warrant, with each whole warrant entitling the holder to purchase one share, at the price of C$1.10 per share, until September 9, 2023. “Over the last four years, LexaGene has constantly been gaining momentum. This financing will allow us to complete the transformation of going from strictly an R&D company, to one that is supporting manufacturing and sales,” Dr. Jack Regan, CEO and founder of LexaGene, said in the news release. “This is a very exciting time to be part of LexaGene as we look to make an impact on multiple market verticals.”

To view the full press release, visit http://ibn.fm/PP33C

About LexaGene Holdings Inc.

LexaGene is a molecular diagnostics company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press “go.” The MiQLab analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time “PCR” assays onto the instrument to target any genetic target of interest. For more information, visit the company’s website at www.LexaGene.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Recent Board Appointments Combine Deep Experience, Expertise to Drive Strategic Vision

September 8, 2020

September 8, 2020 13:24:26

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, recently announced board appointments to align expertise with the company’s strategic vision. These recently appointed board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring to POAI more than a century of invaluable combined experience and life-science, business-development, marketing and financial expertise. An article discussing this quotes POAI CEO Dr. Carl Schwartz, who stated, “These appointments signify our absolute commitment to aligning our board’s expertise with the company’s strategic vision of developing and commercializing an offering that will enable us to support the improvement in health-care outcomes for oncology patients and increase value to our shareholders. Each of these members brings a wealth of knowledge, experience and thought leadership that will be highly valuable as we execute our plans to develop and market AI-based predictive models that leverage our unique tumor bank.”

To view the full article, visit http://ibn.fm/E4i9X

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Light, Finsen and the Use of UV Light to Kill Harmful Bacteria

September 8, 2020

September 8, 2020 13:21:13

Many are counting on researchers and scientists to find treatments that could help manage coronavirus and eventually, a cure for the virus. However, not everyone is fully aware of the ups and downs of scientific discoveries that involve various clinical trials, testing on both animal and human subjects and the failures that come with these speculations.

Take for instance, just over a century ago, Niels Ryberg Finsen began his experimentation with the use of UV light to treat ailments. As there were no subjects who would’ve offered to be his test subjects, Finsen…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

3D Microscopy Reveals How Human Sperm Swim

September 8, 2020

September 8, 2020 11:22:38

For more than thirty decades, researchers have had the knowledge that sperms have been swimming by moving their tails side by side. It has been so because they have been using the 2D microscopes in making that observation. However, the real movement of the sperms has been discovered by the scientist using the 3D microscopy.

How Human Sperms Move

Sperms spin with a wobbly amorphic twist. It is the opposite of what had been known before about the movement of the sperms. Scientists used a very high-speed camera that can record more than 56,000 frames in a second to determine the sperms’ direction. Additionally, they also used a microscope assembled with a piezoelectric device capable of moving…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Cyberattacks: How to Up Your Cybersecurity Game for Medical Devices

September 4, 2020

September 4, 2020 13:03:45

In the healthcare industry, cyberattacks have become very common. This is mainly due to the increase in the networked medical devices. This is prompting device manufacturers to constantly reduce threats that would affect the devices’ security.

Many medical devices have embedded computer systems that are susceptible to security breaches which can affect how they operate. The rise in cyberattacks led to the FDA issuing a warning in March 2019, concerning 2 security flaws that affected implantable…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Wearable Patch Could Ease Sleep Apnea Monitoring at Home

September 4, 2020

September 4, 2020 09:54:15

Sleep apnea is one of the complications that you may experience, and it may bring some difficulties in your sleep. To know that you have this complication, you must spend a night at the health center where its screening can be done. You will be linked with sensors which will be measuring your blood oxygen levels, brain activity, and your eye movement. However, for effective detection of sleep apnea, a group of researchers have developed a wearable that has the capability of tracking your breath. The device uses a combination of electric signals and machine algorithms.

What is sleep apnea?

It is a condition in which your breathing can be disrupted as you sleep either by physical obstruction of the throat by the surrounding muscles or when the neural signals controlling your breath are disturbed. This condition may affect the quality of your life. In some instances…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Lessons from NYC’s Attempts to Make Medical PPE

September 3, 2020

September 3, 2020 14:27:40

An organization of 14 unions, hospitals and makerspaces have been organizing, distributing and creating protective equipment’s and face shields to doctors and frontline nurses. The first delivery was done on March 22 and comprised of 97 shields. The group has the capacity of producing from 600 to 1100 shields in one day. Additionally, the organization also has maker’s and engineers who are focused on putting their varying facilities and skills to use. Here are key lessons that can be picked from their initiative.

Getting Input from Nurses and Doctors

The group became majorly known because of getting input from nurses and doctors. Since the group has not yet been certified or approved by the FDA, they are the last options for various health care workers. The PPE has, however, been well researched…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Progress Report on Critical Steps for Manufacturing of Leading Drug Candidate

September 3, 2020

September 3, 2020 10:16:18

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has provided updated information on the manufacturing of its lead drug candidate, Berubicin. The company announced it has reached key milestones in the manufacturing process as it has followed a dual-track, drug-product manufacturing strategy; CNS is working with both U.S.-based Pharmaceutics International Inc. (“Pii”) and Italy-based BSP Pharmaceuticals S.p.A. (“BSP”) in producing Berubicin. “As we prepare to initiate our upcoming Berubicin clinical trials, our execution both on the clinical and manufacturing fronts remain paramount to our success,” stated CNS Pharmaceuticals CEO John Climaco in the press release. “We continue to be encouraged as our partner Pii has now delivered upon many of the critical steps necessary to ensure the quality and availability of Berubicin. We look forward to keeping you updated on our progress as we continue our preparations to submit an IND for Berubicin during the fourth quarter of this year.”

To view the full press release, visit http://ibn.fm/b0y81

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States., while a sublicensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Digital Contact Tracing: Helping Flatten the COVID-19 Curve

September 3, 2020

September 3, 2020 09:09:22

With the coronavirus pandemic still affecting most countries globally, researchers advocate for the use of digital contact tracing as a means to reduce the spread of the virus.

Private Kit: Safe Paths, is an app developed by the MIT Media Lab with Ramesh Raskar, an associate professor at the lead. This app boasts of being able to perform digital contact tracing while protecting the privacy of persons. It has been speculated that the app might be integrated with Waze for COVID-19, an official WHO app that is also…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CASMS: Testing Medical Equipment Supply Safety for COVID-19

September 2, 2020 14:22:18

With the increase in demand for Personal Protective Equipment as well as other medical supplies, especially for the frontline workers who risk their lives every day during this pandemic period, many well-meaning innovators around the world have taken this up as an opportunity to help out by making this equipment readily available. These include nasal swabs, 3D-printed face shields, ventilator machines as well as open-source oxygen concentrator.

However, despite the many designs of protective gear out there, few meet the minimum safety standards required. To address this problem, a group was formed collectively known as CASMS (Collaborating to Address Shortages of Medical Supplies). The group was created by Mike Dempsey, who is also the Director of the CIMIT Accelerator Program. CASMS group comprises of individuals from CIMIT and was formed with the intention of making sure that basic standards were being met in the creation of medical supplies. That way, both safety…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Carmakers Start Making Respirators Face Masks and Ventilators

September 2, 2020 14:09:54

The arrival of COVID-19 caught everyone unaware, especially in the healthcare sector and it led to a shortage of respirators, face masks, and ventilators. The sudden lack of this equipment has made automobile manufacture to venture into the production of these special medical PPE and equipment.

Ford’s efforts in manufacturing ventilators

Since automobiles’ sales have been affected by the pandemic, the vehicle manufacturing industries such as Ford are venturing into the production of respirators and ventilators. Though they are not experts in this field, they have decided to partner with the experts to produce the required ventilators, respirators, and face masks. For a standard ventilator to be manufactured, it requires…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) CEO Discusses Transformation to B2B2C Digital Therapeutics

September 2, 2020 13:28:14

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, has recently achieved a series of successes and anticipates even more in the coming weeks. Among drivers of DRIO’s path toward leading cutting-edge solutions is the global pandemic, which has unveiled dynamics of the company’s business model that provide distinction in an era in need of next-generation health care. A recent article discussing this includes commentary from DarioHealth’s CEO Erez Raphael, who stated, “The COVID-19 pandemic has accelerated our ongoing transformation to a business-to-business-to-consumer (‘B2B2C’) digital therapeutics leader. We advanced late-stage discussions with health plans and self-insured employers who we believe recognize how our industry-leading user engagement and satisfaction metrics lead to improved health for their member and employee populations. . . . We believe that we are poised to announce new and potentially transformational agreements in the next few weeks.”

To view the full article, visit http://ibn.fm/uYNu1

About DarioHealth Corp.

DarioHealth is a leading, global, digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. The company’s cross-functional team operates at the intersection of life science, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario offers one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new geographic markets to address chronic conditions using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DarioHealth are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) to Evaluate Psilocybin in Methamphetamine Use Disorder Treatment Clinical Trial

September 2, 2020 11:41:48

Revive Therapeutics (CSE: RVV) OTC: RVVTF), a specialty life-sciences company focused on the research and development of therapeutics for medical needs and rare disorders, has finalized a clinical trial agreement with the Board of Regents of the University of Wisconsin System (“UWS”). The agreement calls for Revive Therapeutics to conduct a clinical study entitled “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.” The agreement calls for Revive Therapeutics to have an option to obtain an exclusive, worldwide, royalty-bearing commercialization license to all rights, title and interest that UWS may obtain in any invention resulting from the clinical study. “We are delighted to be collaborating with clinical researchers at the University of Wisconsin‒Madison to advance development of psilocybin for the potential treatment of methamphetamine use disorder,” Revive’s CEO Michael Frank in the press release. “We are building a pipeline of clinical-stage psychedelic-derived therapies for addiction disorders with a focus on psilocybin with unique dosage forms.”

To view the full press release, visit http://ibn.fm/aMSs4

About Revive Therapeutics Ltd.

Revive is a life-sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders. The company is prioritizing drug-development efforts to take advantage of several regulatory incentives awarded by the Food and Drug Administration (“FDA”) such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of cannabidiol (“CBD”) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints New VP to Oversee Regulatory Affairs

September 2, 2020 10:24:19

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has appointed William E. Gannon Jr., MD, MBA, as vice president of Regulatory Affairs. With more than three decades of experience in the biotech and pharmaceutical industries and an impressive background in oncology and gene therapy, Gannon brings invaluable expertise in the areas of clinical development, regulatory affairs and commercialization of products. He is currently chief scientific officer and medical director at Capital City Technical Consulting, where he has directed clinical trial development and operations management for clients in both the biotech and pharmaceutical industries. In his new role at Genprex, Gannon will oversee the company’s clinical trials, including those that combine Genprex’s lead drug candidate, GPX-001 for non-small cell lung cancer (“NSCLC”), with AstraZeneca’s targeted therapy Tagrisso(R) and with immunotherapy Keytruda(R). “We are pleased to have Dr. Gannon join our team,” said Genprex chairman and CEO Rodney Varner in the press release. “His extensive experience in the management of clinical trials, from designing trials to building operational teams, will be an important asset for us as we work toward initiating our upcoming trials and seeing them through to successful completion.”

To view the full press release, visit http://ibn.fm/U4r0S

About Genprex Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Slated for Presentation at Prestigious LD 500 Virtual Investor Conference

September 2, 2020 09:43:44

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that company executives will be presenting at LD Micro’s elite LD 500 Virtual Investor Conference. The presentation is scheduled for Wednesday, Sept. 2, 2020, at 3:40 p.m. ET. An archived copy of the webcast will be available for 90 days following the live presentation.

To watch the live webcast of the presentation, visit http://ibn.fm/QS1EB

To view the full press release, visit http://ibn.fm/Pcn1n

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

How Stay-at-Home Orders Are Impacting the Vulnerable

September 1, 2020

September 1, 2020 14:01:48

Several countries have had to put in place strict measures to curb the spread of COVID-19. Some of these measures include the restriction of movement and lockdowns. These measures have brought significant challenges to the less fortunate in most countries. Furthermore, several economies are crumbling, and some nations cannot comfortably feed their citizens.

Effects of COVID-19 on the Vulnerable

A group of experts are undertaking some surveys to determine the extremity of COVID-19 stay-at-home orders upon the vulnerable groups in society. The experts will use all the mechanisms, including artificial intelligence, to fully determine the effects of coronavirus on these groups. Some of the areas that they will be focusing on include loss of jobs, domestic violence, wage loss and the reduction…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

The Numerous Benefits of Neural Implants

September 1, 2020

September 1, 2020 09:53:37

A neural implant or brain implants are technological devices that are connected to a person’s brain. They are placed on an individual’s brain or connected to the brain’s cortex. This device then interacts with the brain’s neurons. They can be inserted through an injection or surgery. Neurons are cells responsible for relaying information in a person’s body using electrical signals.

Neural implants have many uses. These include treatment of various diseases, rehabilitation of the body after injuries, enhanced memory as well as aiding communication…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Why Healthcare Professionals Should Utilize Social Media

August 31, 2020

August 31, 2020 12:00:53

As you join medical school, one of the first things that you will undergo during the orientation period is watching instructional videos. The videos are always about social media and what you should do and what you should not do as an upcoming healthcare professional. For long periods now, healthcare worker, were advised against the use of social media, especially when at work.

As a physician, there are some things that you are not supposed to do at all costs. For instance, you are not supposed to post the patients’ personal information, expose medically…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Steps to Take Before Drug Patents Expire

August 31, 2020

August 31, 2020 10:09:46

It would be best if you always had strategies that you can use when your drug patent is about to lose its exclusivity. As your drug patent expires and the generic competition emerges, your branded drugs will automatically lose more than 40% of their sales to generic formulations. It is therefore always essential to come up with strategies for you to have a soft landing spot in case your drug patent expires. These are some of the steps you may consider taking as your drug patent approaches its expiry:

The conventional therapy against the return hits that come with the loss of exclusivity include:

You may delay provisional generic entry to the market via a pediatric license indication
You can develop a product line extension with the capability of patent protection
Engage in short-term promotional marketing and sales plans

It would help if you were informed that these strategies are useful for every drug. However, they are the typical first line strategy against the economic…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Mistakes to Avoid When Planning a Drug Launch

August 28, 2020

August 28, 2020 13:39:25

Launching a new product is always a huge undertaking. Though your company has managed to enter the market on several occasions, not every moment will resemble or will be successful as other moments. As you launch your new drug into the market, several factors must be put in place to ensure that your drug launch is successful. Note that without following proper launching procedures, your entry into the market may fail.

Though mistakes are sometimes inevitable, you should try to avoid them during this important function. If your firm is gearing towards launching its novel drug…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Exciting Opportunity for Clinical Quality Professionals Coming in Fall 2020

August 28, 2020

August 28, 2020 12:12:10

Clinical Document World promises to be the year’s learning and networking event for life science professionals. The virtual event, produced by Lincoln Health Network and slated to take place from Sept. 15-18, 2020, is designed to enhance attendees’ clinical trial document process in order to have a complete Trial Master File (“TMF”) as well as enable their businesses to improve clinical quality, implement new technology and be inspection ready. Clinical Document World offers over 45 educational sessions that cover all aspects of clinical document management, including regulatory guidance, compliance, quality, and technology. Ideal attendees are life science professionals from pharmaceutical, biotech and medical device organizations with responsibilities in clinical documentation, TMF, inspection readiness, clinical operations, and others. Over 40 industry leaders with expertise in clinical operations, TMF, quality, technology, and inspections will share insight and discuss advancements and innovations to implement and deploy for enhanced document management.

To view the full press release, visit http://ibn.fm/4bOub

About Lincoln Health Network

Lincoln Health Network is the pharmaceutical, medical devices, and life science go-to source for thought leadership and industry news. Research is driven through industry case studies – providing actionable data, benchmarking and insights into leading programs. Along with leading regulatory and compliance information, Lincoln Health Network’s events provide a dynamic platform for professionals to gain new education, expand networks and drive business results. Each conference, summit and workshop connects decision makers with networking, technology solutions and cutting-edge, peer-driven content. To learn more, visit www.LincolnHealthNetwork.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Maximizing the Value of Drug Patents Before Losing Exclusivity

August 28, 2020

August 28, 2020 08:26:59

When you lose your drug patent exclusivity, it does not mean that you have lost your income when. Your anxiety may be awakened if only a new drug competitor enters the market. However, you can still ensure that your product still reaps big profits even if your drug patent is approaching loss of exclusivity. These are some of the ways you can maximize product value as a loss of exclusivity looms:

Early Planning

You should start developing your loss of exclusivity plans for your product at least two years before your drug patent expires. You can begin to implement this plan before you lose your exclusivity. If you wait till the last minute, you will minimize the efficiency…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Pandemic Warning Signs We Missed

August 27, 2020 14:30:45

You never knew that there would be a pandemic, and you had never seen anything like this before. No one would ever have imagined a thing like this will strike. However, before COVID-19 hit the world, several people had already issued warnings about the pandemic. Those people included medical experts, famous authors, and presidents. These people were issuing warnings in conferences, televisions, and government reports. Here are some of the seven warning signs about the pandemic that we ignored:

UNC Specialists warned about the emergence of coronavirus (2015-2016)

A famous coronavirus epidemiologist at the University of North Carolina had been warning about the outbreak for several years. In a remarkable article termed as the Nature Medicine, the epidemiologist predicted a possible risk of SARS-COV re-emergence from the viruses circulating in the population of bats. In 2016 in a paper known as PNAS, he further warned that the virus outbreak…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (PCSA) Enters Exclusive Agreement to Expand Pipeline, Oncology Involvement

August 27, 2020 14:04:24

Processa Pharmaceuticals (OTCQB: PCSA), today announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (“PCS6422”) globally. According to the update, PCS6422 is an oral drug designed to be administered with fluoropyrimidine cancer drugs (i.e., “capecitabine,” “5-FU”) in order to decrease their breakdown to inactive metabolites or metabolites known to cause unwanted side effects and interfere with the anticancer activity. “Having worked on 5-FU and other cancer agents in the past, adding PCS6422 to our pipeline and expanding our involvement in oncology was an easy decision given the significant impact that PCS6422 may have on improving the efficacy and safety of capecitabine or other fluoropyrimidines,” said Processa CEO Dr. David Young in the news release.

To view the full press release, visit http://ibn.fm/4i9Vj

About Processa Pharmaceuticals Inc.

The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions — medical conditions where patients need treatment options that will improve survival and/or quality of life. The company has assembled a proven regulatory science development team, management team and Board of Directors. The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. For more information, visit the company’s website at www.ProcessaPharma.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) and TumorGenesis Advancing Path Toward Patient-Specific Treatments

August 27, 2020 11:42:51

Predictive Oncology (NASDAQ: POAI), together with its TumorGenesis subsidiary, has achieved significant breakthroughs in applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Earlier in June, TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, sold its first order of unique ovarian cancer cell culture media to a New England-based university carrying out research within the sector (http://ibn.fm/lpsCk). A recent article discussing POAI and TumorGenesis reads, “Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. The company’s wholly owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells to be used in assisting researchers and clinicians identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they feed into TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample to enable the development of a patient-specific treatment plan (http://ibn.fm/lpsCk).”

To view the full article, visit http://ibn.fm/2fWmR

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Editorial Projecting Significant Growth for Global Brain Tumor Therapeutics Sector

August 27, 2020 10:10:26

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, was featured in an editorial by Financial News Media. The piece, titled “Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025,” covers CNSP and other biotech and pharma companies, including Mallinckrodt plc (NYSE: MNK), Amarin Corporation plc (NASDAQ: AMRN), Merck (NYSE: MRK) and Immunic Inc. (NASDAQ: IMUX), which are active in the market. Several industry analysts project continued growth in the global brain tumor therapeutics sector, with one such report projecting that it will reach $2.74 billion in 2023. The editorial discusses recent developments and R&D activities that may potentially bring more future treatment options, while, at present, the high cost of brain cancer-specific drugs is currently acting as a restraint.

To view the full press release, visit http://ibn.fm/n2sza

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

5 Factors to Consider When Investing in a Drug Company

August 27, 2020 09:49:14

As your drug patent rights lapse, you can lose billions of money as your new competitors enter the market. This is the main reason why several investors always put their concentration on drug patent rights during the evaluation of drug companies. To help you make better investment decisions, here are some of the main factors to put into consideration if you want to invest in drug companies:

Seek Orphan Drug and Non-Patent Administrative Exclusives

In several states, governments are always using the regulatory agencies’ non-patent individuality, such as those in orphan drugs. They use those exclusivities to incentivize the production of new medicines. This is because the percentage of sales of orphan drugs is always increasing at a faster rate. The orphan drugs are also offered seven years of market exclusivity whether they have the patent rights or not. In some countries, exclusivity…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Positioned to Compete in ‘Largely Untapped US Market’

August 26, 2020 13:15:19

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, recently completed a round of successful fundraising that will assist in expanding the availability of its platform. DarioHealth secured approximately $28.6 million in aggregate gross proceeds from health-care funds and institutions across the United States and Israel through the private-placement transaction with accredited investors. The new capital coupled with existing cash puts the company in its best financial state since its inception (http://ibn.fm/uKWvc). A recent article discussing this quotes Dario CEO Erez Raphael, who stated, “We are pleased to have the confidence of our largest shareholder and several new highly regarded health-care investors as we expand commercial to manage existing and anticipated near-term agreements with health-care payers. The adoption rate of digital therapeutics has been accelerated by the current pandemic. Dario’s efficacious, value-oriented solution is well-positioned to compete in this largely untapped U.S. market.”

To view the full article, visit http://ibn.fm/vtGXU

About DarioHealth Corp.

NOTE TO INVESTORS: The latest news and updates relating to DarioHealth are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology Inc.’s (NASDAQ: POAI) Exclusive Resources Provide Personal Profiling, Tools to Improve Patient Outcomes

August 26, 2020 12:15:48

POAI, Helomics builds AI-driven models that predict drug response, patient outcome
Company tests patient tumor, generates comprehensive picture that oncologists use to individualize therapy
Key to individualized insight is POAI’s Tumor Drug Response Profiling (“TDRP”) platform, NGS-based genomic profiling, unmatched cancer knowledge base

Guided by the mantra that “cancer is personal — we believe therapy should be too,” Predictive Oncology (NASDAQ: POAI) subsidiary Helomics focus on building AI-driven models that will predict drug response and patient outcome of individual tumors. With the largest tumor inventory in the world, POAI leads the way in providing a functional precision medicine approach that harnesses the power of an individual patient’s tumor to personalize their cancer treatment plan.

POAI works closely with oncologists to provide key information to help improve their patients’ odds in their fight against cancer. Helomics current clinical test platform offers a powerful, proprietary approach that tests a patient’s unique tumor, then combines drug-response profiling and genomic profiling of…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Ethical Considerations in Human Biospecimen Collection

August 26, 2020 11:15:41

As researchers are frantically looking for a COVID-19 vaccine and other treatments, safety, and health ethical issues of patients must be highly considered. Some ethical issues, like the anonymity of patients, must be handled with proper attention so as not to affect the esteem of any individual. As a researcher, before using any patient in your clinical trials, you must first obtain written consent from them. You may risk your job in acquiring the biospecimen from patients if you do not seek permission from them.

Also, you should familiarize yourself with your country’s legal and ethical laws regarding human subjects. For instance, several states have different bodies that give consent to research involving human subjects. However, it is always essential to remain professional and uphold…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Engages Worldwide to Further Drive Berubicin’s Clinical Development

August 26, 2020 10:48:20

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently announced its engagement of Worldwide Clinical Trials as the contract research organization (“CRO”) for its upcoming Berubicin clinical trials. Worldwide, which specializes in therapeutic areas where there remain unmet medical needs, is a midsize, global CRO that provides drug development services to biopharmaceutical companies in clinical trials. “Designing and operating trials in areas of high unmet medical need, such as glioblastoma, is a challenging and complex task for any company. We are excited to bring on a high caliber partner such as Worldwide, which has extensive expertise in CNS and oncology, as our CRO for the upcoming Berubicin clinical trials,” said John Climaco, CEO of CNS Pharmaceuticals, in the press release. “Engaging Worldwide is one of the key pieces of our preparations. We maintain that their insight and unparalleled experience in trials of this nature provide the best opportunity to further drive Berubicin’s clinical development. We believe that with Worldwide’s deep clinical CNS and oncology experience, and through our achievements in trial preparation, we are optimally positioned for our upcoming Phase II Berubicin trials in adults in the U.S. and Poland as well as our Phase I pediatric trial.”

To view the full press release, visit http://ibn.fm/Ip98A

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Invited to Present at Prestigious LD 500 Virtual Investor Conference

August 26, 2020 10:13:36

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it joins the lineup of presenters at this year’s LD 500 Virtual Investor Conference. The annual LD Conference spotlights some of the most prominent companies in the micro-cap world, and also includes interviews and keynotes with small-cap leaders. GNPX chairman and CEO Rodney Varner will provde a company overview as well as updates on Genprex’s lead drug candidate, GPX-001, which recently received fast track designation from the U.S. Food and Drug Administration for use in combination with AstraZeneca’s Tagrisso(R) for treatment of late-stage lung cancer with EGFR mutations; the presentation will also include a summary of the company’s preclinical diabetes gene-therapy candidate designed to treat, and perhaps cure, type 1 and type 2 diabetes. Held online for the first time, the elite conference is scheduled for Sept. 1–4; Chalmers’s presentation is slated for 2 p.m. EST on Tuesday, Sept. 1. More information, including how to register, is available at https://ld500.ldmicro.com.

To view the full press release, visit http://ibn.fm/ZMAeb

About Genprex Inc.

Genprex is a clinical-stage, gene-therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes that currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Artificial Intelligence Could Help Eradicate COVID-19

August 26, 2020 08:32:07

The use of artificial intelligence (“AI”) has increased over the years. This has enabled researchers to have the computing powers of higher orders than what was there when COVID-19 first struck. Today, artificial intelligence has significantly been used to find different patterns within large information sets. Furthermore, artificial intelligence is instrumental in helping you to understand better any information that is not characterized. AI can also be used in predicting trends and patterns of the various phenomenon, and this could hold the key to finding a solution to COVID-19.

Incorporating Artificial Intelligence in COVID-19 research

Artificial intelligence works even better with a set of information that has been well characterized. It will help you in picking up trends and patterns, especially when dealing with well-organized sets of data. One laboratory has been using AI in building dynamic, physics-based protein models. The models are to help come up with molecules that can help eradicate COVID-19 viruses as they interact with cells. Additionally, chemistry studies are also capable of generating information that can be used with the AI that can create…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Florida Approves Release of Engineered Mosquitoes to Combat Viral Diseases

August 25, 2020

August 25, 2020 13:38:29

Some of the infectious ailments spread by mosquitoes such as yellow fever, Zika, Chikungunya, and dengue are growing concerns in the U.S. and globally. To successfully combat these diseases, you will have to deal with their vectors effectively. Recently, permission was granted to the piloting program in Florida to release genetically modified mosquitoes to the environment. The initiative is to help combat the spread of these infectious diseases.

The proponent of this project is Oxitec which aims at controlling and combating insect pests such as the medflies, mosquitoes, and diamondback moths. The project has been fully supported by the Florida Keys Mosquito Control District Board of Commissioners (“FKMCD”). The project is now going to be brought to reality after…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Affordable Rapid Covid-19 Test Could Be Available by January

August 25, 2020

August 25, 2020 08:57:50

Scientists from the University of California, Irvine (“UCI”) are soon coming up with a rapid COVID-19 test that could give you your results in hours. The technology which relies on lab-on-a-chip model will also be cost-effective for you. The antibody testing COVID-19 diagnostic test could be available for you by the end of the year.

How the test will work

A blood stain will be obtained through a prick on your finger. The test will probe hundreds of antibody responses to SARS-COV-2, including the other 14 respiratory viruses. Scientists from UCI have conducted more than 5000 tests using this test. The scientists say that identifying viral infections with the same symptoms of COVID-19 will help health institutions determine…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

New Study Shows Blood Test Could Detect Alzheimer’s

August 24, 2020

August 24, 2020 13:01:02

Alzheimer’s disease has been a problem for many people since it leads to progressive memory loss and a degeneration of other essential mental abilities. Without early management, the disease can lead to dementia. Several tests have been put forward to try and detect this disease at its earliest stages.

However, the good news is that a novel and direct blood test could now offer better results as it can detect Alzheimer’s disease’s early symptoms. According to the researchers, despite detecting Alzheimer’s, the new blood test could also show other…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Charity Calls for Additional Screening to Increase Cancer Survival Rates

August 24, 2020

August 24, 2020 09:26:17

Cancer awareness among the general public is essential and a foundation upon which cancer-control plans can be built. Cancer awareness and survival rates can be boosted by understating the existing problems and exploring possible solutions. This is the reason as to why a charity foundation in the UK has called for increased screening for cancer across several regions. The foundation has also retaliated that stalling the numbers being examined has been the main stumbling block in saving the lives of patients with cancer.

Comparative screening of cancer

It has been noted that cancer screening of individuals who see their general practitioners (“GPs”) with symptoms of cancer is the main reason why such countries have better survival rates than the UK. A complete reconstruction of how cancer is treated should therefore be implemented. Currently, for a patient to be screened, it is the doctors…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

New Blood Test Could Eliminate Unnecessary Chemotherapy Treatment

August 21, 2020

August 21, 2020 12:52:32

Cancer is one of the deadliest diseases affecting humans and is also ranked as one of the highest killer diseases. Since there is no specific drug that cures it, surgery has been used as a standard procedure in treating early forms of cancer to remove the tumors. However, in its advanced stages, chemotherapy always comes in to salvage the situation, though surgery is ever taken as a precaution to prevent cancer from recurring once it has been treated. Many patients have been subjected to chemotherapy as a treatment for cancer, but they never needed it in the real sense.

Benefits and dangers of chemotherapy

Chemotherapy can be unpleasant and dangerous though it can be improved. Groups of researchers are trying to improve the situation to come up with better ways of treating cancer. Researchers are coming up with a blood test that could determine if the patient has the risk of having a recurrence of cancer. While chemotherapy is an essential and life-saving treatment to cancer, patients should not receive it unnecessarily. Avoiding unnecessary chemotherapy…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers Say Heart Attack Blood Tests Have Major Flaws

August 21, 2020

August 21, 2020 10:05:03

Several tests have been developed to determine heart attack risks, some of which have been successful. Still, new tests are being developed, with the latest being a blood test used to determine whether the patient has had a blood attack. However, researchers have noted that the existing blood tests have shortcomings in deciding whether the patient has had an attack.

Determining the weakness in the heart attack blood test

Proteins such as troponin were measured in these tests, and one in twenty cases showed surprising results. The blood test was conducted on 20,000 patients; out of which it was discovered that 5% of the patients had higher levels of the protein troponin that the minimum required by…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Bladder Cancer Urine Tests Promise Better Treatment Outcomes

August 20, 2020 12:35:01

Some two novel urine tests have been developed that will improve the patients’ outcome for bladder cancer. These tests are significant upgrades of the existing urine tests for bladder cancer. The current urine tests have been inaccurate, invasive, and expensive.

Causes of bladder cancer

Bladder cancer has been causing high death rates as compared to other types of cancer. The many deaths are due to the difficulties and. . .

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Net Element Inc. (NASDAQ: NETE) Announces Merger Agreement with Internationally Distributed EV Company

August 20, 2020 11:23:06

NETE, Mullen Technologies sign definitive merger agreement
Newly formed company will be dedicated to development of environmentally friendly, affordable technology offering energy solutions
Agreement calls for Net Element’s wholly owned, newly formed subsidiary to acquire all outstanding shares of Mullen

Net Element (NASDAQ: NETE), a global financial technology and value-added solutions group, has signed a definitive merger agreement with Mullen Technologies Inc. The agreement outlines a stock-for-stock reverse merger plan resulting in Mullen, a privately held electric vehicle company, and its stockholders owning a majority of the outstanding stock in the post-merger company (http://ibn.fm/5LwBp).

“We are excited to move forward with the proposed merger with Mullen Technologies,” said Net Element executive chairman…

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Lands Milestone Contract with Major Pharmaceutical Company

August 20, 2020 10:54:34

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its Soluble Biotech division has finalized its first major contract since being acquired by POAI earlier this year. The contract calls for a project involving protein expression followed by solubility studies, both areas of expertise for Soluble Biotech. The new POAI division provides soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. “Our first contract is a major milestone and validates our recent move into a new, larger facility,” said former NASA astronaut and Soluble Biotech founder Dr. Larry DeLucas in the press release. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies. With our first contract on the books, and expanded capacity, the future is bright. We are currently negotiating several additional contracts with biotechnology and pharmaceutical companies.”

To view the full press release, visit http://ibn.fm/QGzOs

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Could We Soon Use Apps to Know How Long We Have to Live?

August 20, 2020 10:35:48

Nearly everyone asks themselves a hard question on when they will die. The question prompts different answers as innovations are on the verge of bringing apps that could predict our lifespan.

However, there may be an abuse of these apps, such as invading of people’s privacy. Though as it stands, coming up with an app that will accurately predict one’s life expectancy may be difficult. Success may be halted by other factors such as the genetic composition of an individual. But with the new technology emerging, that app may be brought to…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

The Scale of Covid Pandemic Makes Researchers Consider Crowdsourcing to Raise Funds

August 19, 2020 14:25:41

There have been other pandemics that have been experienced globally before the coming of COVID-19. Also, it isn’t the only the headache the world is battling since there are other problems. For instance, drug-resistant illnesses and environmental degradation are other examples of disasters experienced globally. COVID-19 is gaining special attention due to its nature of rapid multiplication and spread.

Since the information gathering process is still ongoing, the current academic and scientific research cannot respond quickly to disasters like these. However, some ways can be used in overcoming this problem. For example, crowdsourcing is one best method that can be applied to boost biomedical research and development (R&D) and could provide results to tackle pandemics such as COVID-19.

Several promising responses to COVID-19 are ongoing, and several potential vaccines are undergoing various stages of development. However, there is no certainty…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Taking Health Care Home Through Innovative Platform

August 19, 2020 11:39:47

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, is a clear point-of-need innovator in today’s standoffish environment. The company supplies hospitals with next-generation technology to provide patients necessary care as they are “roomed” at home under a remote-monitoring regimen. A recent article discussing this reads, “DarioHealth’s Remote Patient Monitoring (‘RPM’) digital therapeutics platform provides physicians with essential information and also delivers occasional ‘nudges’ to patients when its automated programming recognizes a need (http://ibn.fm/tC5si).”

To view the full article, visit http://ibn.fm/cyAME

About DarioHealth Corp.

DarioHealth is a leading, global, digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario offers one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new geographic markets to address chronic conditions using a performance-based approach to improve the health of users managing chronic disease. For more information about the company, visit https://www.dariohealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DarioHealth are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Scottish Scientist Develops Rapid Ebola Test

August 19, 2020 11:01:57

One of the viruses that have the potential of spreading fastest from one person to the other is Ebola. Ebola outbreaks have been experienced in the recent past, especially in multiple African countries. For these outbreaks to stop, there is a need to develop a quick detection method for the disease. One of the Scottish scientists from the school of Natural Sciences has been working on this rapid test method.

Developing the test

The Scottish scientist has developed the novel testing method for the Ebola virus that can rapidly perform in the field. The good news is that the test can be done even without much-sophisticated equipment. Moreover, every tool required to conduct this test can fit in a small bag mobile laboratory. This makes it suitable…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Shares of DarioHealth Corp. (NASDAQ: DRIO) Reach 52-Week High

August 19, 2020 10:07:34

Shares of DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, reached a new 52-week high on Wednesday. In morning trading, the company’s shares reached a peak of $22.49 on volume of over 170,000, up from an opening price of $18.75. At time of publishing, shares of DRIO hover around $21.35, marking a PPS increase of roughly 13.87% on the day.

About DarioHealth Corp.

DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. For more information about the company, visit www.dariohealth.investorroom.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

New Blood Test Could Provide Timely Detection of Lung Transplant Rejections

August 18, 2020 14:02:58

Persistent transplant failure can be hazardous. Realizing this failure as early as possible is therefore very vital in achieving the best possible patient outcomes. The good news is that a new test has been discovered to help detect the symptoms of this condition in lung transplants. The test detects the signs before any outward symptoms start showing themselves, enabling physicians to act urgently to protect the lives of patients.

Detecting and treating organ transplant failure using the blood sample test

The test was discovered and developed by the Laboratory of Organ Transplant Genomics in the Cardiovascular Branch of the National Heart, Lung, and Blood Institute (“NHLBI”). For the test to work, it requires a simple blood sample to detect early lung transplant failure. The test is also believed…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Scientists Seek to Develop Decoy Cells to Kill Viruses

August 18, 2020 12:39:17

Thousands of researchers globally are working around the clock to develop a vaccine to attack the SARS-COV-2 virus. However, researchers in the nanoengineering laboratories are taking a different way towards dealing with the SARS-COV-2 infection. Besides boosting the immune system to attack and kill the virus, the researchers have opted to create a defense mechanism. The mechanism is to work by shielding healthy human cells that are affected by the virus. The strategy is straightforward as it employs the creating of decoy structures looking like the human cells that the SARS-COV-2 attacks. These decoy cells can then attract and later neutralize the virus, leaving the immune cells healthy.

For the decoy cells to be made, researchers gathered the outer membranes of immune or long cells and wrap them around a core designed from tiny, biodegradable particles. The decoy cells are made to resemble the human cells they are impersonating. These cells are also nanosponges as they can soak up any dangerous pathogens that may attack the cells they are impersonating. Once the virus is locked by these decoy cells…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Sale of 8 Skyline Medical STREAMWAY(R) Systems to Large University Hospital Organization

August 18, 2020 10:51:13

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY(R) System for automated, direct-to-drain medical fluid disposal, has completed the sale of eight systems to a large university hospital organization in Virginia for a new surgical center. According to the update, the organization already has two STREAMWAY systems currently in use. The sale is expected to generate approximately 4,000 annual procedures.

To view the full press release, visit http://ibn.fm/mzHmo

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drives the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based roadmap for therapy. In addition to its proprietary precision-oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

DarioHealth Corp. (NASDAQ: DRIO) Beats Street Q2 Revenue Estimates by 20% and Reveals Late Stage, Virtual Healthcare, B2B2C Sales Pipeline

August 18, 2020 10:38:27

DarioHealth Corp. reported its second quarter financial results Aug. 12, showing a revenue increase on a quarter-to-quarter basis, as well as gross profit increases of 95 percent and 60 percent on year-over-year quarterly and six-month measures, respectively
CEO Erez Raphael recently appeared on Fox Business news forum “The Claman Countdown” to discuss the company’s health and the state of the telemedicine industry amid reports of high-value M&A activity
Telemedicine has gained significant popularity as a means of maintaining health standards while reducing or eliminating the risk of virus transmission during the ongoing COVID-19 pandemic
U.S. President Donald Trump recently signed measures designed to make emergency authorization for insurance reimbursements for telehealth services more permanent beyond the duration of the pandemic, and many private insurers are beginning to follow suit
DarioHealth has gained market attention as it has racked up successes in advancing its remote health monitoring platform for diabetes and hypertension patients where it is commercially available in the United States, Canada, the United Kingdom, Europe and Australia after clearing regulatory hurdles
The company announced its first two remote patient monitoring agreements in North America in June, followed by an agreement covering the United Kingdom and Ireland in July

The innovative energy driving the health technology company DarioHealth (NASDAQ: DRIO) has generated a series of successes for the small-cap company, and DarioHealth is anticipating additional developments in the coming weeks that may help the company continue to grow and mature, according to CEO Erez Raphael in the company’s just-released Q2 financial statement.

“The COVID-19 pandemic has accelerated our ongoing transformation to a business-to-business-to-consumer (B2B2C) digital therapeutics leader,” Raphael stated in the Aug. 12 statement…

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Aegis Capital Corp. Initiates Coverage, Issues ‘Buy’ Rating on DarioHealth Corp. (NASDAQ: DRIO)

August 17, 2020

August 17, 2020 13:11:12

Aegis Capital Corp. has initiated coverage with a ‘Buy’ rating and price target of $25 on shares of DarioHealth’s (NASDAQ: DRIO) stock. DRIO is a pioneer in the global digital therapeutics (“DTx”) industry with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The report reads, “We initiate coverage on DRIO with a BUY rating and $25 PT based on a 5.6x EV/Sales multiple applied to FY:21E sales of $11.4mm, a discount to the est. peer average of 8.1x. We believe this multiple is warranted thanks to the growth prospects and quality of the product offering, underpinned by published efficacy data, with a modest discount for conservatism. At 6/30, Dario had $13.2mm of cash, and on 7/31, a further $28.6mm in gross proceeds were raised through a private placement.”

For more information about the company, visit www.DarioHealth.InvestorRoom.com.

About DarioHealth Corp.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Engages LaunchWorks for Commercial Release of MiQLab(TM)

August 17, 2020

August 17, 2020 09:52:37

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has engaged LaunchWorks to support the commercial launch of MiQLab(TM) prior to the end of September 2020. “We are making great progress in adding sales and manufacturing to LexaGene’s capabilities. I’m very pleased to announce our partnership with LaunchWorks, which will be responsible for manufacturing the consumables required to operate MiQLab,” Dr. Jack Regan, LexaGene’s CEO and Founder, stated in the news release. “Launchworks can currently manufacture enough products to easily support our commercial launch and have the facilities to scale their production to meet any demands that we require. I am very impressed by their facilities, high caliber staff, and their ability to scale their operations to meet our needs as we grow.”

To view the full press release, visit http://ibn.fm/wvSu4

About LexaGene Holdings Inc.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

How Africa Plans to Create Its Own Medical Technology

August 14, 2020

August 14, 2020 12:05:26

Some technological advancements, such as biomedical engineering, can be used in saving lives because the biomedical engineering field draws knowledge from different disciplines such as computer science, public health, clinical practice and biomedical sciences.

The information from these four areas has been combined to design medical devices for proper…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2020 Results, Business Update and DojoLIVE! Interview

August 14, 2020

August 14, 2020 10:15:41

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Thursday released financial results for the quarter ended June 30, 2020 and provided a business update. “During the second quarter we reached a major milestone in our journey towards full commercialization with the first sale of our novel ovarian cancer cell media to a top-rated medical university in New England,” Dr. Carl Schwartz, Predictive Oncology CEO, stated in the news release. “This sale serves as a solid proof point of our mission and is a significant achievement towards improving healthcare outcomes for cancer patients. Our unique media significantly expands the number of ovarian cancer cell types that can be studied representing nearly 95% of all ovarian cancers, many of which have never been cultured before now, and reduces waste in cancer research.”

In addition, the company today announced that Mark Collins, Ph.D., chief innovation officer of its Helomics subsidiary, recently appeared on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of software companies and startups. The broadcast is titled “Can We Cure Cancer With Artificial Intelligence?” and is available via the DojoLIVE! website for on-demand viewing. During the interview, Collins discussed a passion for applying science to build high-tech products and services that impact the search for new medicines and the unique positioning of Helomics to deliver on this goal.

To view the full press releases, visit http://ibn.fm/ol0FR and http://ibn.fm/aIrPK

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Scientists Develop Tests to Track Skin Cancer Treatment Success

August 13, 2020

August 13, 2020 13:05:39

Cancer has long been a dangerous disease accounting for lots of deaths worldwide. Diagnosing and treating it has also become a big challenge because as the tumors grow, the old cancer cells are replaced by the newly formed ones. These cells then die off, releasing their DNA into the bloodstream of the patient. However, new blood tests have been developed to help in diagnosing it. The new blood test has been designed to aid in treating skin cancer and the tests have proven to be effective after a few days of drug therapy.

Researchers from the Perlmutter Cancer Center and those from the NYU School of Medicine tracked the circulating tumor DNA (“ctDNA”) for the cancer genes in blood samples of patients with stage…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Connecting Medicine and Engineering Could Hold the Key to Better Healthcare

August 13, 2020

August 13, 2020 09:34:37

Engineering and medicine have been synchronized in various ways. For instance, prosthetic hips, bedside monitors, artificial valves and MRI machines emerged due to the interface of medicine and engineering. Since medical and health records involve the storage of big data, artificial intelligence and personalized medicine can attest to the importance of engineering in medicine.

Rise of Biomedical Engineering

Engineering faculties have been preparing for the future of biomedical engineering. They have to induct their students to learn the concepts and tools of engineering and how to apply them in the biomedical field. For example, designing implants capable…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

New DNA Test Could Detect Several Cancers Simultaneously

August 12, 2020 14:35:42

As the latest innovations are cropping up daily, the health sector is also enjoying those benefits. Several methods of testing and detecting various diseases are being developed day by day. For instance, identifying conditions like cancer at the early stages is growing as the day goes by, and recent discoveries show that any disease can now be detected at its most initial stage.

Detecting Cancer Through DNA Evaluation of Fragments for Early Interception Packaging

A novel test has been discovered recently which can detect different kinds of cancer from blood samples. Researchers have developed the new method at the Johns Hopkins Cancer Center, which relies on original DNA packaging. The technique does not rely on tumors…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – FWD Pharma 2020 to Shine Spotlight on Impactful Digital Trends in Today’s Shifting Landscape

August 12, 2020 11:09:21

Lincoln Health Network’s second annual FWD Pharma Conference is set to draw an engaging lineup of marketing and brand practitioners from leading organizations and shine the spotlight on biotech and life-science strategies in a complex digital world. Slated to be held Aug. 31-Sept. 1, 2020, the event promises to amplify attendees’ digital transformation of commercial operations and market access through omnichannel engagements, campaign analytics and marketing automation. FWD Pharma 2020 will feature keynotes, interactive panels, case studies, hands-on workshops, and peer-to-peer learning opportunities. A diverse group of marketing and brand practitioners from leading life-sciences organizations will share successful strategies to instigate critical organizational change and insight on digital trends most prominent in today’s shifting landscape.

To view the full press release, visit http://ibn.fm/0NJo5

About Lincoln Health Network

Lincoln Health Network is the pharmaceutical, medical devices and life sciences go-to source for thought leadership and industry news. Research is driven through industry case studies – providing actionable data, benchmarking and insights into leading programs. Along with leading regulatory and compliance information, Lincoln Health Network’s events provide a dynamic platform for professionals to gain new education, expand networks and drive business results. Each conference, summit and workshop connects decision makers with peer networking, technology solutions and cutting-edge, peer-driven content. To learn more about Lincoln Health Network, visit: www.LincolnHealthNetwork.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Seek Answers Explaining Why Bones of Diabetics Are Fragile

August 12, 2020 10:08:57

People with type two diabetes are more likely to suffer broken bones than non-diabetic persons. As the number of people with diabetes rises, the skeletal brittleness in persons with type two diabetes is also increasing, and much is not known about the reasons responsible for this reality. The bone’s fragility is usually attributed to its density, but that is not the case with type two diabetes patients since they have normal bones. The puzzle is that they still suffer from fractures at a very high rate. However, researchers are on the verge of establishing the cause of these high fragilities in bones.

Are bones alive?

Like other living organs, bones are also alive. Bones are responsible for the structural integrity and protection of the body. Furthermore, red blood cells are produced within bones. The red blood cells are responsible for the production of valuable minerals such as phosphorus and calcium. When broken, bones can heal on their own or through medical interventions. However, bones are always in the state of constant repair through a process known as remodeling.

Wear and tear on bones happens daily due to the physical activities that people undertake. However, they are constantly repaired since this happens in micro-structures. The repairing process involves…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Q2 Revenue, Overview of Key Company Highlights and Development

August 12, 2020 09:33:30

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released a business update, including financial numbers and corporate achievements for the second quarter ended June 30, 2020. Highlights of the report include the company’s announcement of two Remote Patient Monitoring (“RPM”) agreements in the United States as well as an agreement with Williams Medical, which allowed Dario to enter the United Kingdom. In addition, the company reported Q2 revenues of $1.79 million, a 7.2% sequential increase from Q1 2020. “The COVID-19 pandemic has accelerated our ongoing transformation to a business-to-business-to-consumer (B2B2C) digital therapeutics leader,” said Dario CEO Erez Raphael in the release. “We advanced late-stage discussions with health plans and self-insured employers, who we believe recognize how our industry-leading user engagement and satisfaction metrics lead to improved health for their member and employee populations. Our pipeline continues to grow and mature, and although the normal sales cycle can be lengthy, we believe that we are poised to announce new and potentially transformational agreements in the next few weeks.”

To view the full press release, visit http://ibn.fm/U5RoZ

About DarioHealth Corp.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Drug Homing Method Could Offer New Insights into Parkinson’s

August 11, 2020 16:25:16

The most complex and least-understood organ in the body is the brain and it is made up of many specialized areas that work together. Now modern methods, such as pharmacology and gene editing, can show how certain drugs and genes affect the cells in specific regions of the brain.

Causes of neuropsychiatric disorders

A researcher, Michael Tadross, MD, PhD, has developed a method to ensure that any drug injected into an area of the brain will only affect the targeted cell type. The researcher genetically modified a cell type of interest so that the special receptor protein known as the HaloTag is expressed at the cell membrane. Besides, the drug of interest is modified so that it can be chained with the molecule…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

3D Model Provides Insights on How to Treat Bomb Injuries

August 11, 2020 12:31:34

For thousands of people who have suffered terrible blast injuries, the only remedy to this is always amputation. Barrel bombs and other explosive devices usually cause the worst form of these injuries.

These explosions are dangerous, damaging the limbs of those who survive them. Since most of these blasts still occur in developing nations without sophisticated medical care, the victims are continuously…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Members; Adds Depth of Knowledge, Experience to Strengthen Company’s Vision

August 11, 2020 12:24:17

Appointments signify POAI’s commitment to aligning board’s expertise with company’s strategic vision
Board members to support development, commercialization of unique offering that improves outcomes for oncology patients, value to shareholders
New appointments effective immediately

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, announced the appointment of three new highly qualified individuals to its board of directors (http://ibn.fm/YAU80). The three new board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring with them more than a century of invaluable experience in business development, marketing and financial expertise in the life-sciences space.

“These appointments signify our absolute commitment to aligning our Board’s expertise with the company’s strategic vision of developing and commercializing an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value to our shareholders,” said POAI CEO Dr. Carl Schwartz…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shareholder Letter Highlights Achievements, Discusses Two Key Proposals

August 11, 2020 10:13:32

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, outlined the company’s recent accomplishments in a letter released to shareholders. The letter, sent from CEO Dr. Carl Schwartz, also summarized voting recommendations from POAI’s Board of Directors regarding two proposals that are scheduled for shareholder vote next month. “Predictive Oncology is committed to executing our strategic vision to develop and commercialize an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value for our shareholders,” stated Schwartz in a press release containing the letter. “Over the last six months we have been diligently assembling a portfolio of assets and aligning our capital and governance structures to help us achieve this vision.”

To view the full press release, visit http://ibn.fm/Epqmf

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Can Neuro-Doping Technology Boost Performance?

August 10, 2020 14:35:37

Several doping techniques among athletes are coming up due to new technology. One of the methods known as neuro-doping, is currently legal. The technique involves sending electric currents to one’s brain, hence facilitating rapid learning, improved coordination, and muscular strength.

Neuro-doping in sports

Sportsmen and women have been enthralled by this electronic doping, which has replaced other doping techniques banned by the World Anti-Doping Agency (“WADA”). It is the latest doping method and WADA has yet to come up with rules governing neuro-doping and its detection. As per now, most of the athletes…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – BioMedWire to Serve as Official Newswire for FWD Pharma Conference and Strategic HCP Partnerships Summit

August 10, 2020 13:43:18

BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of many brands part of the InvestorBrandNetwork (“IBN”), today announced its collaboration with the FWD Pharma Conference, scheduled to be held Aug. 31-Sept. 1, 2020, as well as participation in the Strategic HCP Partnerships Summit, slated for Nov. 18-20, 2020. According to the update, IBN will serve as the official media sponsor and BioMedWire will serve as the official newswire of both events. “We have enjoyed working with the Global Strategic Management Institute on multiple events in the past and are looking forward to continuing that relationship,” Jonathan Keim, communications director for InvestorBrandNetwork, stated in the news release. “FWD Pharma has an impressive approach to joining industry professionals with interactive panels, case studies and hands-on workshops to help attendees truly understand the importance of today’s digital journey.”

To view the full press release, visit http://ibn.fm/as1PU

About BioMedWire

BioMedWire is a specialized communications platform, one of 50+ brands within our InvestorBrandNetwork, that aggregates and distributes news and information on the latest developments in the life sciences sector. Designed to quickly update investors on important industry news, BioMedWire is committed to keeping the public abreast of the latest developments related to emerging market opportunities in the sector. For more information, visit www.BioMedWire.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Featured in Fox Business Segment Regarding Telehealth and the Future

August 10, 2020 10:49:36

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, was featured in a Fox Business segment on Friday titled, “Is telehealth the future of health care?” Dariohealth CEO Erez Raphael joined Fox’s Liz Claman to explain where he sees digital health and digital therapeutics going from here. “In order to treat chronic conditions, it’s very, very important to surround the user 24/7, and digital solutions and digital therapeutic solutions, such as Livongo, is a solution for chronic condition management,” Raphael stated, referring to Livongo Health Inc.’s (NASDAQ: LVGO) solution in a recent collaboration with Teladoc Health Inc. (NYSE: TDOC). “I think that this is the first of many transactions and mergers that we’re going to see in the space of digital health and digital therapeutics.”

To view the full news segment, visit http://ibn.fm/jlxtD

To view the DarioHealth infographic, please visit http://ibn.fm/js9e8

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, DarioHealth empowers individuals to make adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit www.DarioHealth.com

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

How Wi-Fi Could Help Patients Breathe Easier

August 10, 2020 08:20:57

Technology has helped a lot of people to monitor their homes remotely. It has been amazing to use smart doorbells and thermostat applications. Could such techniques also be imported to the health sector? It is possible to cooperate with such technologies, such as Wi-Fi based devices, which may aid patients with breathing difficulties. There are multiple ways that Wi-Fi based devices can be used in delivering oxygen to patients.

The internet is the technology that allows several tools used daily to be connected to a computer, and innovators are aiming to link the hospital’s oxygen concentrators to an app. This will enable physicians to monitor…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Why People Hate Winter

August 7, 2020 14:35:08

Winters are always categorized with frozen mud, icy winds, and musty parkas. It is also a dark-induced season characterized by a lot of rainfall, making a lot of people sad. Furthermore, it is always accompanied by cold temperatures. However, research shows that there are two categories of people who can tolerate cold temperatures; men and indigenous Arctic groups like the Siberians. Since many people live in these cold areas, they need to acclimate and adapt to these areas.

Adapting to cold climates

For many years, people living in cold climates have been evolving. For instance, some are stout with shorter limbs. It makes them have a small surface area compared with their body mass from which to lose heat. Research shows that people from these regions also tend…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Marks Milestone in Applying AI to Find New Targets for Treatment, Diagnostics

August 7, 2020 12:30:38

Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis and working with distributor US Biological Corporation, has accomplished a major achievement. Recently, the company announced its first-ever commercial order of a novel ovarian cancer cell culture media for cancer cells collected from patient-derived samples (“PDx”) (http://ibn.fm/2xwl6). An article discussing this quotes Richard Gabriel of TumorGenesis, who states, “Capturing and culturing and then being able to study ovarian cancer cell types has always been limited by the ability to grow reproducible cultures that reflect what is in the patient. We now have isolated and grown 25 ovarian cancer cell types, 11 of that library represents nearly 95% of all ovarian cancers, many of which have never been cultured prior to this time. This new media will allow researchers around the world to isolate and then culture ovarian cancer cell types and culture them reproducibly to find new targets for treatment, diagnostics or other studies on the close interrelationship of ovarian cancer tumor populations and how they are able to fool a patient’s immune system.”

To view the full article, visit http://ibn.fm/WHrN6

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – DarioHealth (NASDAQ: DRIO) Announces Plans to Release Q2 Financials, Provide Company Update

August 7, 2020 09:45:20

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, will release its second-quarter earnings on June 30, 2020, as well as host a 9 a.m. ET conference call and webcast on the same day. Hosted by CEO Erez Raphael, president and North America general manager Rick Anderson, and CFO Zvi Ben-David, the call will include a business update as well as an earnings discussion. Interested parties are invited to participate by dialing 1-844-369-8770 (in the United States) or 1-862-298-0840 (internationally) or visiting http://ibn.fm/wQKu5. Those who are participating are asked to dial in or log in 10 minutes prior to the start of the event. In addition, a recording of the earnings call will be posted approximately two hours after the conclusion of the call and will remain available through Aug. 26, 2020. To access that recording, dial 1-877-481-4010 (domestic) or 1-919-882-2331 (international) and use replay passcode 36466. The webcast recording will be available through Nov. 12, 2020.

To view the full press release, visit http://ibn.fm/QqO17

About DarioHealth Corp.

DarioHealth Corp. is a leading, global, digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. DRIO’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain-Controlled Exoskeletons Set to Help Paraplegics Walk

August 7, 2020 08:35:09

Bipedal robots have, for a long time, been struggling to walk like human beings and they have tried balancing and moving forward without falling. It has taken several years of hard work; and now the robots are starting to get comfortable with the art of walking. Their walking technique is putting them in a position of helping persons in need.

How robotic-assisted mobility works

Roboticists have launched an initiative called Robotic-Assisted Mobility Science (“RoAMS”). RoAMS is using the latest research in robotic walking in creating a new kind of medical exoskeleton. These exoskeletons can move actively using neurocontrol interfaces. The exoskeletons will also allow users to balance and walk without…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Facial Recognition and Thermal Scans Could Soon Be Normal at Building Entrances

August 6, 2020

August 6, 2020 14:18:50

Since the pandemic struck, temperature screening has been used to find those that are infected with COVID-19, and this has made your body temperature to be no longer private information. Your body temperature is soon becoming like a pass for you to access buildings. Most business premises are installing thermal imaging cameras that are fitted with facial recognition technology. They are doing so to come to terms with the COVID-19 pandemic.

Thermal scans installation in public institutions

Office buildings, government offices, fast food restaurants, airports, hospitals, and universities are quickly adopting technology. The main aim is spotting and turning away any person getting into those buildings with a fever. Theoretically, it will reduce…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

DarioHealth Corp. (NASDAQ: DRIO) Obtains Significant Capital Infusion with $28.6 Million Investment Round

August 6, 2020

August 6, 2020 11:49:28

DarioHealth Corp. is an digital therapeutics (“DTx”) pioneer supplying remote health condition monitoring technology to caregivers and their patients
The company recently reported a successful private placement funding transaction that provides Dario with $28.6 million in aggregate gross proceeds to build Dario’s operational strategy
Dario’s technology allows clinical care providers to remotely observe data related to patients’ chronic conditions and also may “nudge” patients to sustain their own care
The novel coronavirus pandemic has increased the popularity of remote patient monitoring (“RPM”) services as a means of avoiding infection risks in public healthcare settings, and legislative changes have made it easier to receive insurance reimbursement for those services

Modern technology has opened the door for a revolution in healthcare services, allowing many patients with chronic diseases to lead full and active lifestyles that may take them far from their medical providers without significant fear of repercussions thanks to communication media that support expansive health networks and, of late, telehealth and remote patient monitoring measures.

DarioHealth (NASDAQ: DRIO), a digital therapeutics innovator dedicated to providing such technology to hospitals and other medical facilities to help ensure patients receive a proper standard of care even if they are not in-clinic, recently announced a round of successful fund-raising that will help the…

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Americans Distrust Contact Tracing Apps, Survey Finds

August 6, 2020

August 6, 2020 10:32:22

A lot of confusion and disbelief is stalling digital contact tracing efforts during the COVID-19 pandemic. A new survey shows that less than 50% of the American respondents support contact tracing apps. This indicates a lack of trust in deploying the technology and could even hinder its effectiveness.

How digital contact tracing apps work

Several contact tracing apps always try to collect some data about a smartphone user’s encounters with other people. Thereafter the app will notify the users if they are potentially coming into contact with a COVID-19 patient. However, each app works differently from the other in terms of privacy. For example, some apps collect data based on GPS, while others record…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Portable Vagus Nerve Stimulator Cleared for Emergency Use During Coronavirus Pandemic

August 5, 2020

August 5, 2020 14:08:43

The U.S. Food and Drug Administration has allowed the emergency use of a non-invasive Vagus nerve stimulator in treating COVID-19 patients. The handheld device designed by electroCore works by sending a train of electric pulses through the skin to a nerve in the neck. The pulse train causes the airways in the lungs to open, and it may also have an anti-inflammatory effect.

How to use the device

The gamma Core Sapphire CV device can be used both in clinics, hospitals, and at home. They can be used in treating adults with suspected or known cases of COVID-19. Adults should be showing increasing asthma-related symptoms, reduced airflow, and those whose drug therapies are not tolerated or provide…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Rides Deal Wave to Stock Bump

August 5, 2020

August 5, 2020 12:36:05

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, is riding a wave that pushed its stock up 20% with no DRIO-related news. An article published to MarketWatch today titled, “UPDATE: Teladoc and Livongo Health to merge in deal valued at $18.5 billion,” covers a move amid a trend toward virtual healthcare that places DRIO, a provider of digital health solutions, in the right place at the right time. The article reads, “Teladoc Health Inc. (NYSE: TDOC) and Livongo Health Inc. (NASDAQ: LVGO) said Wednesday they have agreed to merge in a deal valued at $18.5 billion to create a company that can serve a spectrum of health needs, using virtual care. Under the terms of the deal, Livongo shareholders will receive 0.592x shares of Teladoc plus $11.33 in cash per share owned. Teladoc shareholders will own about 58% of the combined entity, while Livongo shareholders will own the remaining 42%. The combination ‘creates a global leader in consumer centered virtual care,’ the companies said in a joint statement. The new entity is expected to have pro forma revenue of about $1.3 billion for 2020, equal to pro forma growth of 85%.”

To view the full press release, visit http://ibn.fm/IB93S

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Scientific Productivity of Women Drops During COVID-19 Pandemic

August 5, 2020

August 5, 2020 09:05:18

When the coronavirus struck in mid-March, most research work was put on hold. However, virologists had to remain active in studying different viruses similar to SARS-COV-2, a virus that causes COVID-19. It also led to the closure of schools and daycares, meaning women had to take responsibility of nurturing their children since they perform most of the work needed to raise kids.

Pandemic worsens existing inequalities

For a long time now, women have been underrepresented in scientific productivity. According to recent statistics, underrepresentation has increased by over 31%. Furthermore, these numbers have constantly reduced since the pandemic struck. Gender disparities have not only been seen in the research labs but also the submission of research…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Pets Could Harbor a Lot More Than Coronaviruses

August 4, 2020

August 4, 2020 13:38:02

The presence of SARS-COV-2 in cats and dogs has caught the attention of scientists. Many scientists have been researching whether the pets can transmit other pathogens, such as drug-resistant bacteria, to human beings.

Effects of multidrug-resistant organisms crossing from pets to humans

A puppy had exhibited some signs of the coronavirus in North Carolina after three people from the family that owned it had tested positive for the disease. There were concerns about whether the pup had contracted the disease or not. However, after testing samples, the results…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

How Synthetic Biology is Accelerating Drug Discovery

August 4, 2020

August 4, 2020 09:05:29

Synthetic biology is becoming an important tool in a wide range of applications. In the sector of drug discovery, there are many areas where synthetic biology has played a vital role in faster and accurate drug development at lower expenses. With an increased application of DNA sequencing, synthetic biology is becoming essential to biotech and pharma scientists.

Furthermore, the tool has empowered drug discovery scientists to clone and synthesize DNA fragments to develop new drugs. Through it, researchers have resorted to automated platforms for rapid DNA synthesis. This technology is being looked at to generate…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

5 Trends Likely to Appear in Future Pharmaceuticals

August 3, 2020

August 3, 2020 13:56:31

The medical sector is rapidly acknowledging the benefits of digital health, though there is still some sluggishness in embracing those innovations. However, these innovations need to be adopted with the speed they require. Here are some of the trends that are likely to be seen in the pharmaceutical industry in the years to come.

Digital health will revolve around the pill

Most of the pharmaceutical industries are noting that it is not only adequate to produce and manufacture medicine. Future trends show that they should go past the natural…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Predictive Oncology Inc. (NASDAQ: POAI)’s TumorGenesis Presents at Precision in Drug Discovery & Preclinical Virtual Summit

August 3, 2020

August 3, 2020 10:53:45

TumorGenesis president Richard Gabriel selected to feature as keynote presenter at inaugural Drug Discovery & Preclinical Virtual Summit
The summit features over 150 delegates from across bio-pharmaceutical industry coming together to market sector’s latest breakthroughs
TumorGenesis, which specializes in creating laboratory-grown cancer cells directed towards ovarian cancer research, recently announced its first sale of cancer cell culture media to US university
The global cell culture media market set to grow to over $2.4 billion per annum by 2024

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has revealed that Richard Gabriel, President of POAI’s subsidiary TumorGenesis, presented at the upcoming Precision in Drug Discovery & Preclinical Virtual Summit on July 23, 2020 (http://ibn.fm/8N14a).

TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, announced earlier in June that the company had sold its first order of unique ovarian cancer cell culture media to a…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Medical Specialties Poised to Be Huge in Future

August 3, 2020

August 3, 2020 09:05:20

Sensors, artificial intelligence, and virtual reality are some of the advanced technologies that have changed the pharmaceutical sector, and many of these technologies will allow physicians to focus on what makes them good at treating patients. Digital health will also help doctors in performing some of the repetitive tasks that are always monotonous. However, with these six medical specialties, healthcare is poised to benefit greatly.

General Practice

Several doctors are choosing this specialty to make long term impacts on patients’ lives. Furthermore, general practice specialists boast a lot of trust from their patients. The GPs have also reduced the patient’s time moving from one doctor to the other. They can diagnose an illness, give therapy, and offer health advice. With the wearables that relay a patient’s information to doctors notifying…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

The Challenges of TB Detection

July 31, 2020 14:05:40

Mycobacteria tuberculosis complex (“MTBC”) is the pathogenic bacteria causing tuberculosis (“TB”). On the other hand, nontuberculous mycobacteria (“NTM”) is also another bacterium that has the potential to cause disease. Mycobacteria are organisms living in water, animal tissues, soil, and food sources.

The organisms can conquer their hosts without showing any pathogenic signs and can cause serious infections. Infections by MTBC and NTM organisms have continued posing a lot of challenges to microbiologists and physicians globally. Their exclusive cell wall component…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Closes $28.6M Private Placement to Fund Long-Term Operating Plan

July 31, 2020 13:00:13

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has completed a private placement transaction resulting in aggregate gross proceeds of an estimated $28.6 million. After deducting placement agent fees and other offering expenses, capital from the transaction, along with existing balance sheet cash, will be used to fund DRIO’s long-term strategic operating plan. “We are pleased to have the confidence of our largest shareholder and several new highly regarded healthcare investors as we expand our commercial to manage existing and anticipated near-term agreements with health care payers,” said Dario CEO Erez Raphael, chief executive officer of Dario. “The adoption rate of digital therapeutics has been accelerated by the current pandemic. Dario’s efficacious, value-oriented solution is well-positioned to compete in this largely untapped U.S. market.”

To view the full press release, visit http://ibn.fm/utz7J

About DarioHealth Corp.

DarioHealth is a leading, global, digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario offers one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new geographic markets to address chronic conditions using a performance-based approach to improve the health of users managing chronic disease. For more information, visit the company’s website at www.DarioHealth.com

NOTE TO INVESTORS: The latest news and updates relating to DarioHealth are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO Again Featured on ‘Big Biz Show,’ to Present at Proactive’s One2One Virtual Investor Forum

July 31, 2020 10:15:07

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, on Thursday announced participation by its chairman and CEO, Rodney Varner, in a second-round live interview on the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show. A replay of the interview is available for viewing on the company’s website. In addition, Genprex today announced that it will present at the Proactive Investors One2One Virtual Event at 1:40 p.m. ET on August 4, 2020. Varner will deliver a company overview, provide updates on its product pipeline, including its lead drug candidate, GPX-001, and discuss the company’s preclinical diabetes gene therapy candidate that may have the potential to cure type 1 and type 2 diabetes. Interested parties may register for the event at http://ibn.fm/XsTbH.

To view the full press releases, visit http://ibn.fm/hVHDT and http://ibn.fm/ltdRI

About Genprex, Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s “Tagrisso(R)”) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

6 Factors Fueling Antimicrobial Resistance

July 31, 2020 08:33:54

Drug resistance is a serious medical concern and poses a severe health threat in the medical fraternity. In this regard, antimicrobial resistance is one of the worst nightmares that most patients suffering from various infections continue to grapple with across the world.

Generally, antimicrobial resistance results in adverse effects by bacterial infections leading to acute strain on the patient, which…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Could the COVID19 Crisis Be Compromising Research Quality?

July 30, 2020 13:48:33

Is the quality of research being compromised during the COVID-19 crisis? It is a question that should be asked by those who are involved in research expeditions. Research studies are crucial in coming up with discoveries; hence a lot of work ethics is always regarded. However, some loopholes may erupt, leading to some questions regarding the quality of research.

Scrutinizing research exceptionalism

The COVID-19 pandemic has continued to erode the norms of scientific research. As nations observe the ongoing efforts to understand and defeat theSARS-Cov2-Virus, clinical and laboratory studies have been conducted at supersonic speeds. Data has been generated…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Integrate Proprietary Database with CoRE to Drive Drug Discovery, Development

July 30, 2020 13:06:57

Predictive Oncology (NASDAQ: POAI) has completed a strategic move to accelerate commercialization of its proprietary artificial intelligence “AI”-driven drug discovery and development. A recent article discussing Predictive Oncology’s recent acquisition of Quantitative Medicine (“QM”), a biomedical analytics and computational biology company, quotes POAI CEO Dr. Carl Schwartz, where he states, “This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing. Integrating QM’s proven machine-learning platform, CoRE, with our proprietary database of drug response and genomics profiles is expected to revolutionize the role of our AI-driven predictive models in the discovery and development of new anti-cancers.”

To view the full article, visit http://ibn.fm/5VAH1

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

DarioHealth Corp. (NASDAQ: DRIO) Platform Meets Patients’, Physicians’ Remote Care Needs Amid Pandemic

July 30, 2020 12:41:26

DarioHealth Corp. is a digital therapeutics innovator that supplies remote monitoring technology to caregivers and their patients
The company’s Remote Patient Monitoring (“RPM”) technology reports patient data to care providers in the clinical setting and if necessary provides occasional “nudges” to patients to maintain their level of care
DarioHealth began working in North America with two agreements announced in June, and in July began offering its solutions to the United Kingdom and Ireland thanks to a third agreement
Such remote services have been increasingly in demand amid the ongoing global pandemic, regarded as a solution for minimizing the risk of exposure to viral infections and improving hospitals’ capacity to accept the most critical care needs

When the novel coronavirus began to create a surge of infections during the spring in the Northeastern states, some hospitals such as Mount Sinai in New York and Atrius Health in Boston turned to their “hospital at home” (“HaH”) programs to limit the risk of patient exposure to the virus and to keep hospital beds available for the most critically ill amid the growing health crisis (http://ibn.fm/aPjBk).

“We began thinking about how we could use hospital-at-home to meet the needs of our hospital system in our community. … Rather than focusing on specific diagnoses, our focus has been on specific services that we’re able to render at home — and whether those are the services that are keeping the patient in the hospital,” Mount Sinai’s HaH Director Al Siu stated in a…

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Announces First Commercial Sale of Unique Ovarian-Cancer-Cell Media

July 30, 2020 11:22:05

POAI’s TumorGenesis inks deal with top-rated medical university in New England
Predictive’s proprietary media allows researchers around the world to isolate, culture ovarian cancer cell types, leading to new targets for treatment
The TumorGenesis media retain more than 95% of the DNA and RNA as well as crucial proteomic signatures

Predictive Oncology (NASDAQ: POAI) has sold its first-ever commercial order of its novel ovarian cancer cell culture media for cancer cells collected from patient-derived samples (“PDx”) (http://ibn.fm/2xwl6). The sale, made through POAI’s subsidiary TumorGenesis working with distributor US Biological Corporation, marks a milestone for the knowledge-driven company, which is focused on applying artificial intelligence to personalized medicine and drug discovery.

“Capturing and culturing and then being able to study ovarian cancer cell types has always been limited by the ability to grow reproducible cultures that reflect what is in the patient,” said Richard Gabriel of TumorGenesis…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

* 2015-Freedman et al-The Economics of Reproducibility in Preclinical Research; PLOS Biology DOI:10.1371/journal.pbio.1002165 June 9, 2015

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Tips for Safeguarding Intellectual Property Rights Affordably